DE69131882T2 - Asiloglycoproteine des hepatitis c-virus - Google Patents

Asiloglycoproteine des hepatitis c-virus

Info

Publication number
DE69131882T2
DE69131882T2 DE69131882T DE69131882T DE69131882T2 DE 69131882 T2 DE69131882 T2 DE 69131882T2 DE 69131882 T DE69131882 T DE 69131882T DE 69131882 T DE69131882 T DE 69131882T DE 69131882 T2 DE69131882 T2 DE 69131882T2
Authority
DE
Germany
Prior art keywords
virus
proteins
hepatitis
asiloglycoproteine
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69131882T
Other languages
English (en)
Other versions
DE69131882D1 (en
DE69131882T3 (de
Inventor
Robert Ralston
Frank Marcus
Kent Thudium
Barbara Gervase
John Hall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27417050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69131882(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE69131882D1 publication Critical patent/DE69131882D1/de
Publication of DE69131882T2 publication Critical patent/DE69131882T2/de
Application granted granted Critical
Publication of DE69131882T3 publication Critical patent/DE69131882T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE69131882T 1990-11-08 1991-11-07 Asiloglycoproteine des hepatitis c-virus Expired - Lifetime DE69131882T3 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US61141990A 1990-11-08 1990-11-08
US61196590A 1990-11-08 1990-11-08
US611419 1990-11-08
US75888091A 1991-09-13 1991-09-13
US758880 1991-09-13
PCT/US1991/008272 WO1992008734A1 (en) 1990-11-08 1991-11-07 Hepatitis c virus asialoglycoproteins

Publications (3)

Publication Number Publication Date
DE69131882D1 DE69131882D1 (en) 2000-02-03
DE69131882T2 true DE69131882T2 (de) 2000-05-04
DE69131882T3 DE69131882T3 (de) 2007-05-24

Family

ID=27417050

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131882T Expired - Lifetime DE69131882T3 (de) 1990-11-08 1991-11-07 Asiloglycoproteine des hepatitis c-virus

Country Status (17)

Country Link
EP (2) EP0842947B2 (de)
JP (8) JPH06504431A (de)
AT (1) ATE188220T1 (de)
AU (1) AU668078B2 (de)
CA (2) CA2095521C (de)
CZ (1) CZ289006B6 (de)
DE (1) DE69131882T3 (de)
DK (2) DK0556292T4 (de)
ES (1) ES2139591T5 (de)
FI (1) FI107803B (de)
GR (1) GR3032771T3 (de)
HU (2) HUT66063A (de)
NO (2) NO304380B1 (de)
PT (2) PT99466B (de)
RO (1) RO115446B1 (de)
SK (3) SK286106B6 (de)
WO (1) WO1992008734A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274148B1 (en) 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
JP3158177B2 (ja) * 1991-10-08 2001-04-23 国立感染症研究所長 Ｃ型肝炎診断薬
WO1993015193A1 (en) * 1992-01-31 1993-08-05 Abbott Laboratories Mammalian expression systems for hcv proteins
UA39944C2 (uk) * 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
WO1994026306A1 (en) 1993-05-12 1994-11-24 Chiron Corporation Conserved motif of hepatitis c virus e2/ns1 region
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
ATE417109T1 (de) 1994-07-29 2008-12-15 Novartis Vaccines & Diagnostic Hepatitis c e2 verkuerzte polypeptid sowie verfahen zu seiner herstellung
EP1845108A3 (de) 1994-07-29 2007-10-24 Innogenetics N.V. Monoklonale Antikörper gegen gereinigte Hüllproteine des Hepatitis-C-Virus für diagnostische und therapeutische Zwecke
PT773957E (pt) * 1994-07-29 2005-11-30 Chiron Corp Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos
IT1271593B (it) * 1994-11-30 1997-06-04 Sanitaria Scaligera Spa Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
FR2744725B1 (fr) * 1996-02-09 1998-04-30 Pasteur Institut Anticorps specifiques des complexes formes par les glycoproteines e1 et e2 du virus de l'hepatite c, procedes de determination de la presence, et d'isolement de ces complexes
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
KR100209095B1 (ko) 1996-06-28 1999-07-15 성재갑 C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도
ATE423204T1 (de) 1996-11-08 2009-03-15 Us Gov Health & Human Serv Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
EP0980434B1 (de) 1997-05-06 2009-07-29 Novartis Vaccines and Diagnostics, Inc. Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
EP0947525A1 (de) 1998-03-27 1999-10-06 Innogenetics N.V. Epitope in der viralen Hüllproteine und spezifische Antikörper gegen diese Epitope: Verwendung für die detektion von viralantigene im empfängergewebe
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
EP1947185B1 (de) 2000-08-17 2011-07-20 Tripep Ab HCV NS3/4A kodierende Nukleinsäure
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20030232745A1 (en) * 2001-06-26 2003-12-18 Olson William C. Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
AU2003265454A1 (en) * 2002-08-16 2004-03-03 Ohio University Hepatitis c viral-like particle purification
CA2618429A1 (en) 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US20090214593A1 (en) 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1049686C (zh) * 1987-11-18 2000-02-23 希龙股份有限公司 非ａ和非ｂ肝炎病毒的诊断及疫苗
IL88599A0 (en) * 1987-12-10 1989-07-31 Cell Bio Group Ltd Glycoprotein cell growth modulating materials,their preparation and compositions containing them
HUT54896A (en) * 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
UA41266C2 (uk) * 1990-04-04 2001-09-17 Чірон Корпорейшн Комбінація послідовностей епітопів вірусу гепатиту с (hcv), спосіб виявлення антитіл до вірусу гепатиту с (hcv), набір для виконання аналізу при виявленні антитіл до антигену гепатиту с (hcv)

Also Published As

Publication number Publication date
NO931680D0 (no) 1993-05-07
JP3207155B2 (ja) 2001-09-10
EP0842947B2 (de) 2009-03-18
EP0556292A1 (de) 1993-08-25
GR3032771T3 (en) 2000-06-30
NO972213D0 (no) 1997-05-14
DE69131882D1 (en) 2000-02-03
AU668078B2 (en) 1996-04-26
FI107803B (fi) 2001-10-15
FI932025A (fi) 1993-06-07
PT102022A (pt) 1999-01-29
EP0556292B1 (de) 1999-12-29
HU9301336D0 (en) 1993-10-28
EP0842947A2 (de) 1998-05-20
FI932025A0 (fi) 1993-05-05
JP2001286290A (ja) 2001-10-16
ES2139591T3 (es) 2000-02-16
CA2095521C (en) 2009-06-30
CZ82493A3 (en) 1994-04-13
RO115446B1 (ro) 2000-02-28
HU227498B1 (en) 2011-07-28
NO931680L (no) 1993-06-28
DK0842947T3 (da) 2004-07-26
CA2203443A1 (en) 1992-05-09
PT102022B (pt) 2000-12-29
DK0556292T4 (da) 2006-12-27
HUT66063A (en) 1994-09-28
CA2095521A1 (en) 1992-05-09
JP4056306B2 (ja) 2008-03-05
CA2203443C (en) 2001-08-28
DK0842947T4 (da) 2009-06-08
SK286106B6 (sk) 2008-03-05
SK69097A3 (en) 1997-11-05
NO304381B1 (no) 1998-12-07
EP0556292A4 (de) 1995-01-18
ES2139591T5 (es) 2007-08-01
JPH1171395A (ja) 1999-03-16
PT99466A (pt) 1992-10-30
PT99466B (pt) 1999-04-30
JP2006219503A (ja) 2006-08-24
JP2003174875A (ja) 2003-06-24
WO1992008734A1 (en) 1992-05-29
JPH06504431A (ja) 1994-05-26
JP2005187479A (ja) 2005-07-14
JP2003093081A (ja) 2003-04-02
JP2008031181A (ja) 2008-02-14
DE69131882T3 (de) 2007-05-24
NO304380B1 (no) 1998-12-07
EP0556292B2 (de) 2006-11-29
ATE188220T1 (de) 2000-01-15
SK285624B6 (sk) 2007-05-03
CZ289006B6 (cs) 2001-10-17
SK44293A3 (en) 1993-08-11
NO972213L (no) 1997-05-14
DK0556292T3 (da) 2000-04-17
AU9026791A (en) 1992-06-11
SK285623B6 (sk) 2007-05-03
EP0842947B1 (de) 2004-04-21
EP0842947A3 (de) 2001-12-12

Similar Documents

Publication Publication Date Title
ATE188220T1 (de) Asiloglycoproteine des hepatitis c-virus
DE69826661D1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
ATE229543T1 (de) Polypeptide des hepatitis c-virus (hiv)
EP0608261A4 (de) Zusammensetzung aus einem immunreaktiven hepatitis-c-virus-polypeptid.
ATE423204T1 (de) Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln
AU7234987A (en) Viral vector coding for a glycoprotein of the virus responsible for a.i.d.s., vaccine and antibody
EP1471073A3 (de) Asialoglykoproteine von Hepatitis C virus
FI971702A (fi) Hepatiitti-C-viruksen asialoglykoproteiinit
RU93043621A (ru) Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты
KR890701745A (ko) O-결합 글리코실화가 감소된 바이러스 단백질
EP0888046A4 (de) Verfahren zur proteinproduktion mittels eines mitochondrialen translationssystems.
EP0385394A3 (de) Polyhedringen und gentechnologische Anwendung
EP0234862A3 (de) Expression rekombinanter Proteine in Hefe
PT89041A (pt) Metodo de preparacao de diagnosticos e vacinas nanbv

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC., EMERY, US

8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US